1,1,1-trifluoro-2-iodoethane

We are 1,1,1-trifluoro-2-iodoethane CAS:353-83-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   1,1,1-trifluoro-2-iodoethane
CAS.NO:353-83-3
Molecular Formula: ：C2H2F3I
Molecular Weight:209.93700

Synonyms:
trifluoro iodoethane
Trifluoroethyl iodide
EINECS 206-541-0
2,2,2-Trifluoroiodoethane
2-Iodo-1,1,1-trifluoroethane
2,2,2-trifluoro-1-iodoethane
1,1,1-Trifluoroiodoethane
Ethane, 1,1,1-trifluoro-2-iodo-
2,2,2-Trifluoroethyl Iodide
1-iodo-2,2,2-trifluoroethane
1,1,1-trifluoro-2-iodo-ethane

Physical and Chemical Properties:
Density: 2.13 g / mL at 25 ° C (lit.)
Boiling point: 54.8 ° C (lit.)
Flash point: 53-55 ° C
Refractive index: n20 / D 1.401 (lit.)

Specification:
Appearance:Clear colorless to pink Liquid
Purity:≥98.0%
Moisture Content: 0.25%
Impurity: 0.3%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: An important raw material and intermediate used in Organic Synthesis,Pharmaceuticals.

Related News: Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list.methyl 3,3-dimethylacrylate The fine and functional chemicals sector provides new growth drivers.1244029-51-3 An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.89763-93-9 An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.